Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study

Clinical Infectious Diseases

Volumn 63, Issue 6, 2016, Pages 776-783

  Feld, Jordan J ^a   Maan, Raoel ^a,b   Zeuzem, Stefan ^c   Kuo, Alexander ^d   Nelson, David R ^e   Di Bisceglie, Adrian M ^f   Manns, Michael P ^g   Sherman, Ken ^h   Frazier, Lynn M ⁱ   Sterling, Richard ^j   Mailliard, Mark ^k   Schmidt, Monica ^l   Akushevich, Lucy ^m   Vainorius, Monika ^m   Fried, Michael W ^m  

^a UNIVERSITY OF TORONTO   (Canada)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY OF CINCINNATI   (United States)

ⁱ Liver Wellness Center   (United States)

^j VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^l UNIVERSITY OF NORTH CAROLINA   (United States)

^m LEVINE CANCER INSTITUTE   (United States)

more..

Author keywords

cirrhosis; genotype 3; interferon; ribavirin; sofosbuvir

Indexed keywords

ALBUMIN; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CHRONIC HEPATITIS C; CLINICAL TRIAL; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INSOMNIA; IRRITABILITY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT RESPONSE; ADOLESCENT; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; YOUNG ADULT;

EID: 84995514108     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw387     Document Type: Article

References (42)

1. Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56:1261-8.
2. Hill EE, Herijgers P, Claus P, Vanderschueren S, Herregods M-C, Peetermans WE. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J 2007; 28:196-203.
3. Pinholt M, Ostergaard C, Arpi M, et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006-2009: a populationbased cohort study. Clin Microbiol Infect 2014; 20:145-51.
4. Luzzaro F, Ortisi G, Larosa M, Drago M, Brigante G, Gesu G. Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagn Microbiol Infect Dis 2011; 69:363-9.
5. Shaked H, Carmeli Y, Schwartz D, Siegman-Igra Y. Enterococcal bacteraemia: epidemiological, microbiological, clinical and prognostic characteristics, the impact of high level gentamicin resistance. Scand J Infect Dis 2006; 38:995-1000.
6. Mohee AR, West R, Baig W, Eardley I, Sandoe JAT. A case-control study: are urological procedures risk factors for the development of infective endocarditis? BJU Int 2014; 114:118-24.
7. Fernández Guerrero ML, Goyenechea A, Verdejo C, Roblas RF, de Górgolas M. Enterococcal endocarditis on native and prosthetic valves: a review of clinical and prognostic factors with emphasis on hospital-acquired infections as a major determinant of outcome. Medicine (Baltimore) 2007; 86:363-77.
8. erson DJ, Murdoch DR, Sexton DJ, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. Infection 2004; 32:72-7.
9. Fernández-Guerrero ML, Herrero L, Bellver M, Gadea I, Roblas RF, de Górgolas M. Nosocomial enterococcal endocarditis: a serious hazard for hospitalized patients with enterococcal bacteraemia. J Intern Med 2002; 252:510-5.
10. Dahl A, Rasmussen RV, Bundgaard H, et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation 2013; 127:1810-7.
11. Bruun NE, Habib G, Thuny F, Sogaard P. Cardiac imaging in infectious endocarditis. Eur Heart J 2014; 35:624-32.
12. Bouza E, Kestler M, Beca T, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. Clin Infect Dis 2015; 60:528-35.
13. Chirouze C, Athan E, Alla F, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clin Microbiol Infect 2013; 19:1140-7.
14. Dahl A, Bruun NE. Enterococcus faecalis infective endocarditis: focus on clinical aspects. Expert Rev Cardiovasc Ther 2013; 11:1247-57.
15. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633-8.
16. Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, outcome. Medicine (Baltimore) 1995; 74:191-200.
17. Munõz P, Kestler M, Bermejo J, Bouza E. Reply to Tubiana et al. Clin Infect Dis 2015; 61:132-4.
18. Billington EO, Phang SH, Gregson DB, et al. Incidence, risk factors, outcomes for Enterococcus spp. Blood stream infections: a population-based study. Int J Infect Dis IJID 2014; 26:76-82.
19. Min JK, Spencer KT, Furlong KT, et al. Clinical features of complications from transesophageal echocardiography: a single-center case series of 10, 000 consecutive examinations. J Am Soc Echocardiogr 2005; 18:925-9.
20. Probst A, Dang T, BochudM, EggerM, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat 2011; 18:745-59.
21. van der Meer AJ, Hansen BE, Fattovich G, et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut 2015; 64:322-31.
22. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32:2117-38.
23. Duarte-Rojo A, Heathcote EJ, Feld JJ. 'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field? J Hepatol 2011; 55:466-73.
24. Feld JJ. Interferon-free strategies with a nucleoside/nucleotide analogue. Semin Liver Dis 2014; 34:37-46.
25. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-77.
26. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
27. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
28. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015; 61:769-75.
29. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015; 149:1462-70.
30. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236.
31. American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, treating adults infected with hepatitis C virus. Hepatology 2015; 62:932-54.
32. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 2016; 150:419-29.
33. Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol 2015; 62:286-93.
34. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-31.
35. Al Marzooqi SH, Feld JJ. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 2015; 35:1923-33.
36. Younossi ZM, Stepanova M, Estep M, et al. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. J Hepatol 2015; 64:29-36.
37. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127-35.
38. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 2016; 63:1430-41.
39. Hezode C, de Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program. International Liver Congress, European Association for the Study of the Liver, Vienna, Austria, 2015.
40. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149:1454-61.
41. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608-17.
42. Poordad F, Landis CS, Asatryan A, et al. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int 2016; doi:10. 1111/liv. 13067.